The use of intraperitoneal chemotherapy for gastric malignancies

Macrì, Antonio; Morabito, Federico

doi:10.1080/14737140.2019.1671189

Cited by 23 publications

(27 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior studies have reported the recurrence rate for gastric cancer after radical surgery to be 30-50%; peritoneal recurrence was also reported to be seen in 10-46% of patients after radical gastrectomy. 3,11 Patients with peritoneal recurrence usually have a poor prognosis and a survival time of less than 5 months. Intravenous chemotherapy was found to neither significantly lower the rate of peritoneal recurrence nor improve prognosis for patients with peritoneal gastric cancer recurrence.…”

Section: Discussionmentioning

confidence: 99%

“…A total of two patients suffered peripheral blood leukocyte counts ˂3500/mm, 3 while none suffered abnormal liver function tests (serum bilirubin level >3 times or liver enzymes >3 times ULN) or abnormal renal function tests (serum creatinine level >1.5 mg/dl). The incidence of abnormalities in HIPEC patients was similar to that in non-HIPEC patients.…”

Section: Postoperative Recoverymentioning

confidence: 99%

“…1 Postoperative recurrence, especially in the form of intraperitoneal metastases, is the main cause of death. [2][3][4] Studies have reported that over 20% of gastric cancer patients suffer peritoneal metastases either prior to or at the time of surgery, and over 50% of patients suffering T3 and T4 disease suffer peritoneal metastases after radical resection, underscoring the poor prognosis of this condition. [2][3][4] Prior studies have confirmed that cytoreductive surgery in addition to hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improves the prognosis of patients suffering peritoneal gastric cancer metastases.…”

Section: Introductionmentioning

confidence: 99%

“…[2][3][4] Studies have reported that over 20% of gastric cancer patients suffer peritoneal metastases either prior to or at the time of surgery, and over 50% of patients suffering T3 and T4 disease suffer peritoneal metastases after radical resection, underscoring the poor prognosis of this condition. [2][3][4] Prior studies have confirmed that cytoreductive surgery in addition to hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improves the prognosis of patients suffering peritoneal gastric cancer metastases. [5][6][7] Compared with cisplatin and carboplatin, lobaplatin, a third-generation alkylating antineoplastic agent, exhibits good water-solubility, a wide anticancer spectrum and high antitumor activity.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

<p>Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles</p>

Zhong

Zhang

Bai

et al. 2020

CMAR

View full text Add to dashboard Cite

Objective: This study aims to evaluate the safety and efficacy of lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer. Methods: Advanced gastric cancer patients who underwent radical gastric resection and/or prophylactic HIPEC were systematically reviewed in our department from January 2016 to June 2017. All enrolled patients were grouped in either HIPEC or non-HIPEC groups. Clinical data were collected and analyzed. Results: A total of 129 patients were enrolled with 61 cases in the HIPEC group and 68 in the non-HIPEC group. The two groups were well balanced in terms of clinical characteristics. In patients of the HIPEC group, three suffered leakage from the duodenal stump or anastomosis, one suffered abnormal bleeding and two were found to have abnormal routine blood tests; no significant difference in adverse events between groups, however, was noted (p > 0.05) and most patients recovered uneventfully. During follow-up, peritoneal recurrence was significantly less among HIPEC patients (p = 0.029), with only three suffering peritoneal recurrence, as compared to 12 non-HIPEC patients. In addition, the estimated illness-specific 3-year disease-free survival rate was significantly higher in the HIPEC group as compared to the non-HIPEC group (89.4% vs.73.9%; p = 0.031). Conclusion: Lobaplatin in prophylactic HIPEC is safe for advanced gastric cancer patients after treatment by radical resection and can effectively improve illness-specific 3-year disease-free survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Postoperative Recoverymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

<p>Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles</p>

Zhong

Zhang

Bai

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Intraperitoneal approaches have produced unsatisfactory results and there is no accepted standard approach. 4 Molecular characterization of GACs in The Cancer Genome Atlas (TCGA) has provided valuable initial insights into GAC biology. 5 However, all GACs analyzed were sourced from the primary GACs.…”

Section: Introductionmentioning

confidence: 99%

Proteogenomic Landscape of Gastric Adenocarcinoma Peritoneal Metastases

Ajani

Wang

Song

et al. 2020

Preprint

View full text Add to dashboard Cite

Advanced gastric adenocarcinoma (GAC) often leads to peritoneal carcinomatosis (PC) and is associated with very poor outcomes. Therapeutic are limited and effective. Here we report the first proteogenomic study of PC cells from a prospective GAC cohort (n = 26 patients). A total of 16,449 proteins were detected from whole cell extracts (TCEs). PC cells could be classified based on the protein profiles alone into three distinct unsupervised clusters (tumor cell enriched, immune cell enriched and tumor-immune mixed) that differed in expression of oncogene/immune-related proteins. Integrated analysis revealed enriched biological pathways and notably, novel druggable targets (cancer-testis antigens, kinases, and receptors) that could be exploited to develop effective therapies and/or tumor stratifications. Systematic comparison of expression levels of proteins and mRNAs revealed novel expression patterns of key cancer genes notably high mRNA and low protein expression of HAVCR2, low mRNA but high protein expression of cancer testis antigens CTAGE1 and CTNNA2. These results inform strategies to target GAC vulnerabilities.

show abstract